Common CMC Mistakes Emerging Pharma Companies Make

Early development is centered on the science: proving the concept, advancing preclinical work, preparing for funding milestones, and moving toward clinical development. While these priorities are critical, Chemistry, Manufacturing, and Controls can quickly become one of the most important factors influencing whether a program advances smoothly or encounters costly delays.

At Drug Discovery Alliances, we see that CMC decisions made early in development can have long-term implications for product quality, regulatory readiness, manufacturing feasibility, timelines, budgets, and investor confidence. For companies operating with lean teams, the challenge is that many CMC decisions must be made before the organization has built full internal technical infrastructure. That is where experienced guidance and a strong external network can make a meaningful difference.

1. Waiting Too Long to Build a CMC Strategy

One of the most common mistakes emerging companies make is waiting until a regulatory milestone is approaching before developing a clear CMC strategy. By that point, key decisions around process development, analytical methods, manufacturing partners, specifications, and documentation may already be behind schedule.

DDA helps companies think through CMC strategy earlier in the development process by creating a practical, phase-appropriate roadmap. This does not mean every detail must be finalized immediately. Instead, it means identifying what is needed now, what can be developed later, and where technical risks may impact the timeline. A strong CMC strategy helps align scientific goals, regulatory expectations, and business priorities before urgent decisions create unnecessary pressure.

2. Choosing Vendors Based Only on Price

Cost matters, especially for emerging companies with limited funding. However, choosing a CRO, CDMO, or technical partner based only on the lowest price can create long-term problems. A lower initial quote may not account for communication issues, limited technical capabilities, quality gaps, project delays, or the need to repeat work later.

Through DDA’s global network of preferred partners and experienced consultants, companies can better evaluate vendor fit based on technical expertise, quality systems, regulatory experience, communication practices, capacity, scalability, and alignment with the specific stage of development. A strong partner can help preserve time and resources, while the wrong fit can create avoidable delays and added expense.

3. Failing to Plan for Scale-Up

A process that works at a small scale may not work efficiently or reliably at a larger scale. Emerging companies sometimes focus only on producing enough material for the next study or milestone without considering whether the process can eventually support clinical or commercial needs.

DDA works with companies to identify scale-up considerations early, including process robustness, raw materials, equipment needs, analytical testing, quality controls, and manufacturing reproducibility. Even when commercial manufacturing is years away, early awareness of scale-up risks can help companies make smarter development decisions and avoid preventable delays.

4. Not Aligning CMC with Regulatory Strategy

CMC and regulatory strategy should move together. If CMC activities are not aligned with the expected regulatory pathway, companies may find themselves missing required data, relying on unsuitable methods, or needing additional work before a submission can move forward.

DDA helps bridge this gap by connecting technical planning with regulatory expectations and business objectives. A coordinated approach helps ensure that manufacturing, analytical, quality, and regulatory activities are built around the same goals. This alignment is especially important for companies preparing for IND-enabling work, clinical trial material production, or major investor and partner discussions.

5. Overlooking Technical Risk Until It Becomes a Business Problem

Technical issues are common in development, but they become more damaging when they are not identified early. Problems with stability, formulation, impurity profiles, analytical methods, process reproducibility, or supplier reliability can quickly affect timelines and budgets.

DDA’s consultants help companies evaluate technical risks before they become larger business challenges. By reviewing development plans, vendor strategy, timelines, and technical assumptions, DDA helps leadership understand where resources should be focused and which issues may affect future milestones.

6. Managing CMC Activities in Silos

CMC work often involves multiple external partners, consultants, vendors, and internal stakeholders. Without strong coordination, each group may complete its assigned tasks without a clear understanding of how the pieces fit together.

This is one of the areas where DDA brings significant value. DDA supports integrated program management by helping connect technical execution, vendor oversight, regulatory planning, quality expectations, and business goals. For emerging companies that need experienced support but are not ready to build a full internal team, this coordinated model can provide structure, accountability, and momentum.

Conclusion

CMC is not just a technical requirement, it is a strategic function that can influence development speed, regulatory readiness, investor confidence, and long-term product value.

Avoiding common mistakes, such as waiting too long, choosing partners based only on price, failing to plan for scale-up, and managing CMC activities in silos, can help companies move forward with greater clarity and fewer surprises.

Drug Discovery Alliances supports emerging and established pharmaceutical companies by helping them navigate complex development decisions, identify qualified partners, and build practical CMC strategies that support each stage of growth. With experienced consultants and a trusted global network, DDA helps companies turn promising science into executable development plans.